.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical evidence suggests that transdermal estradiol prostate cancer treatment serves as a robust alternative to standard luteinizing hormone-releasing hormone (LHRH) agonists. According to the latest findings from the Phase 3 PATCH trial, this approach provides effective androgen deprivation while significantly altering the toxicity profile for patients. Historically, clinicians used oral estrogen for prostate cancer, but it was largely abandoned due to high cardiovascular and thromboembolic risks. However, transdermal administration avoids the first-pass hepatic metabolism, potentially mitigating these concerns.
In this non-inferiority trial, researchers randomized 1,360 men with locally advanced prostate cancer to receive either transdermal estradiol (tE2) patches or standard LHRH agonists. The results showed a 3-year metastasis-free survival (MFS) of 87.1% in the tE2 group and 85.9% in the LHRH agonist group. Consequently, the study confirmed that tE2 is statistically non-inferior to conventional hormonal therapy. Furthermore, both treatment arms successfully maintained castrate levels of testosterone in 85% of the patients.
While the oncological efficacy was similar, the side-effect profiles varied considerably between the two groups. Men treated with transdermal estradiol prostate cancer patches reported a significantly lower incidence of hot flashes compared to those on LHRH agonists (44% vs. 89%). Additionally, tE2 therapy appeared to preserve bone mineral density and offer better metabolic profiles. Conversely, the incidence of gynecomastia was twice as high in the tE2 arm, affecting 85% of men. Despite this, there were no significant differences in cardiovascular morbidity or mortality between the two groups. Therefore, clinicians can consider tE2 patches as a cost-effective and patient-friendly option, especially for those prioritizing bone health and vasomotor symptom relief.
Yes, the Phase 3 trial demonstrated that 3-year metastasis-free survival was nearly identical between the two groups (87.1% for estradiol vs. 85.9% for LHRH agonists), meeting the criteria for non-inferiority.
Estradiol patches cause fewer hot flashes and help maintain bone density but result in significantly higher rates of gynecomastia compared to LHRH agonists.
No, the study found no evidence of increased cardiovascular mortality or thromboembolic events with patches, as the transdermal route avoids the liver's first-pass effect on clotting factors.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional clinical judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A Phase 3 trial confirms that transdermal estradiol patches are a non-inferior, cost-effective alternative to LHRH agonists for locally advanced prostate ca...
4 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
